Search
Ephrin type-A receptor 5
go.drugbank.com/bio_entities/BE0005587TargetHumansAmong GPI-anchored ephrin-A ligands, EFNA5 most probably constitutes the cognate/functional ligand for EPHA5. … Together with EFNA5 plays also a role in synaptic plasticity in adult brain through regulation of synaptogenesis.
Polypeptides: Ephrin type-A receptor 5Ephrin type-A receptor 4
go.drugbank.com/bio_entities/BE0009438TargetHumansIn the nervous system, also plays a role in repair after injury preventing axonal regeneration and in angiogenesis playing a role in central nervous system vascular formation. … In addition to its role in axonal guidance plays a role in synaptic plasticity.
Polypeptides: Ephrin type-A receptor 4Acyl-coenzyme A thioesterase 1
go.drugbank.com/bio_entities/BE0016368EnzymeHumansCatalyzes the hydrolysis of acyl-CoAs into free fatty acids and coenzyme A (CoASH), regulating their respective intracellular levels.
Polypeptides: Acyl-coenzyme A thioesterase 1Synonyms: Palmitoyl-coenzyme A thioesterase, Inducible cytosolic acyl-coenzyme A thioester hydrolaseSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProducts: SILODOSIN AL 4 MG HKP, SILODOSIN AL 8 MG HKPPindolol
go.drugbank.com/drugs/DB00960ApprovedInvestigationalPindolol is a first generation non-selective beta blocker used in the treatment of hypertension. … [A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348]
Synonyms: 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol, 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-olInternational brands: Blockin L, Blocklin LMagnesium salicylate
go.drugbank.com/drugs/DB01397Approved), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results. … Magnesium salicylate is a non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain. It is available in several over-the-counter (OTC) formulations.
Categories: Non COX-2 selective NSAIDSProducts: Back-ese M Tablets 325 mg, Back-ese M Tab 325mgLacidipine
go.drugbank.com/drugs/DB09236ApprovedIt is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved. … In randomised, well-controlled trials, administration of daily single-dose lacidipine ranging from 2-6 mg demonstrated comparable antihypertensive efficacy similar to that of other long-acting dihydropyridine
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: LACIPIL TABLET 4 mg, LACIPIL 4 MG FILM KAPLI TABLET, 14 ADETPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexProducts: ICLUSIG® 15 MG TABLETAS RECUBIERTAS, ICLUSIG TABLET 45 MGInfluenza B virus B/Wisconsin/1/2010 live (attenuated) antigen
go.drugbank.com/drugs/DB14396ApprovedWithdrawnA seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.
Synonyms: Influenza B virus B/Wisconsin/1/2010 live (attenuated) antigen, Influenza B Virus B/wisconsin/1/2010 Live(attenuated) AntigenEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667]
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: Enzalutamid 1A Pharma 40 mg - Filmtabletten, Enzalutamid 1A Pharma 80 mg - Filmtabletten